Search results for "MESH: Young Adult"

showing 10 items of 22 documents

De novo mutations in the X-linked TFE3 gene cause intellectual disability with pigmentary mosaicism and storage disorder-like features

2020

IntroductionPigmentary mosaicism (PM) manifests by pigmentation anomalies along Blaschko’s lines and represents a clue toward the molecular diagnosis of syndromic intellectual disability (ID). Together with new insights on the role for lysosomal signalling in embryonic stem cell differentiation, mutations in the X-linked transcription factor 3 (TFE3) have recently been reported in five patients. Functional analysis suggested these mutations to result in ectopic nuclear gain of functions.Materials and methodsSubsequent data sharing allowed the clustering of de novo TFE3 variants identified by exome sequencing on DNA extracted from leucocytes in patients referred for syndromic ID with or with…

0301 basic medicineMESH: Basic Helix-Loop-Helix Leucine Zipper Transcription Factors[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyIntellectual disabilityTFE3Biology[SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human geneticsMESH: Intellectual Disability03 medical and health sciencesExon0302 clinical medicineMESH: Whole Exome SequencingMESH: ChildIntellectual disabilityGeneticsmedicineMissense mutationGeneGenetics (clinical)Exome sequencingPigmentary mosaicismMESH: Pathology MolecularGeneticsMESH: AdolescentMESH: HumansAlternative splicingLysosomal metabolismMESH: Child Preschool[SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyMESH: Adultmedicine.diseasePhenotypeMESH: InfantMESH: MaleTFE3Storage disorder030104 developmental biologyMESH: Genes X-Linked[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticsMESH: Young AdultMESH: EpilepsyMESH: MosaicismMESH: Pigmentation DisordersMESH: Female030217 neurology & neurosurgery
researchProduct

TP53 codon 72 polymorphism and cervical cancer

2009

Background Cervical cancer is caused primarily by human papillomaviruses (HPV). The polymorphism rs1042522 at codon 72 of the TP53 tumour-suppressor gene has been investigated as a genetic cofactor. More than 80 studies were done between 1998 and 2006, after it was initially reported that women who are homozygous for the arginine allele had a risk for cervical cancer seven times higher than women who were heterozygous for the allele. However, results have been inconsistent. Here we analyse pooled data from 49 studies to determine whether there is an association between TP53 codon 72 polymorphism and cervical cancer.Methods Individual data on 7946 cases and 7888 controls from 49 different st…

ArginineMESH : Polymorphism GeneticMESH: Genes p53MESH : AgedPhysiologyUterine Cervical NeoplasmsMESH: Papillomavirus Infections[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineGenotypeMESH : FemaleCervical cancerGeneticsMESH: AgedMESH : Papillomavirus Infections0303 health sciencesMESH: Middle AgedHPV infectionMESH: Genetic Predisposition to DiseaseMiddle AgedMESH : AdultWILD-TYPE P53Hardy–Weinberg principle3. Good healthMESH: Uterine Cervical NeoplasmsOncologyMESH: Young Adult030220 oncology & carcinogenesisMeta-analysisFemaleAdultAdolescentMESH : Uterine Cervical NeoplasmsMESH : Young Adult[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Genes p5303 medical and health sciencesYoung AdultSQUAMOUS INTRAEPITHELIAL LESIONSMESH : AdolescentINDIAN WOMENMESH: Polymorphism GeneticmedicineHumansGenetic Predisposition to DiseaseMESH : Middle AgedAllele030304 developmental biologyAgedMESH: AdolescentMESH: HumansPolymorphism GeneticHUMAN-PAPILLOMAVIRUS TYPE-16business.industryP53 ARG72PRO POLYMORPHISMHEALTHY WOMENPapillomavirus InfectionsMESH : HumansMESH: AdultOdds ratiomedicine.diseaseGenes p53GENOTYPESHARDY-WEINBERG EQUILIBRIUMRISK-FACTORSMESH : Genetic Predisposition to DiseasebusinessMESH: FemaleHPV INFECTIONLancet Oncology
researchProduct

Influence of substrate oxidation on the reward system, no role of dietary fibre.

2011

International audience; It has been suggested that a high intake of dietary fibre helps regulate energy intake and satiety. The present study aimed to examine whether dietary fibre influenced the liking and wanting components of the food reward system, the metabolic state or subsequent intake. Five sessions involving 32 normal-weight subjects (16 men and 16 women, 30.6 ± 7.6 year) were held. The sessions differed in the composition of the bread eaten during breakfasts (dietary fibre content varied from 2.4 to 12.8 g/100 g). Several factors such as the palatability, weight, volume, energy content and macronutrient composition of the breakfasts were adjusted. Energy expenditure, the respirato…

Dietary FiberMaleMESH: Oxidation-ReductionMESH: Dietary Carbohydrates030309 nutrition & dietetics[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionsatietyAppetiteMESH: Food HabitsMESH: Energy IntakeChoice BehaviorMESH: EatingEatingIngestionMESH : FemaleFood sciencePalatabilityMESH : Body WeightGeneral PsychologyMESH : Food Habitsmedia_commonMorning2. Zero hunger0303 health sciencesMESH : Food PreferencesNutrition and Dieteticsdietary fibre05 social sciencesdigestive oral and skin physiologyMESH: Energy MetabolismMESH : Feeding BehaviorBreadMESH : AdultMESH : Dietary Carbohydratesreward systemMESH: Young AdultMESH: Feeding BehaviorFemalePsychologyOxidation-Reductionfood preferencesMESH : AppetiteAdultMESH : EatingMESH : Malemedia_common.quotation_subjectMESH : Young AdultSatiationMESH: Choice BehaviorMESH: BreadYoung Adult03 medical and health sciencesReward systemsensation de faimMESH : Choice BehaviorDietary CarbohydratesHumans0501 psychology and cognitive sciences050102 behavioral science & comparative psychologyMESH: Food PreferencesMESH : Oxidation-ReductionMESH: HumansMESH: SatiationMESH : HumansBody WeightDietary fibreMESH : Energy IntakeAppetiteMESH: AdultFeeding BehaviorMESH: MaleMESH: Body WeightMESH : Energy MetabolismRespiratory quotientMESH: Dietary FiberEnergy densityMESH: AppetiteMESH : Dietary FiberEnergy IntakeEnergy MetabolismMESH : BreadmetabolismMESH: Female[SDV.AEN]Life Sciences [q-bio]/Food and NutritionMESH : Satiation
researchProduct

Very preterm birth: who has access to antenatal corticosteroid therapy?

2010

International audience; We describe the administration of antenatal corticosteroid therapy (ACT) for liveborn very preterm neonates in a population-based study. A total of 790 very preterm neonates (between 24 and 31 full weeks of gestation) were included in this regionally defined population of very preterm neonates in France. The main outcome measure was non-access to ACT. Data were analysed using logistic and polytomous models to control for neonatal and sociodemographic characteristics, mechanisms of very preterm birth and neonatal network organisation. As compared with level III, births in levels I-II maternity units were closely related to non-access to ACT (60.1% vs. 8.8%), but not t…

Gestational hypertensionPediatricsEpidemiologyMESH: Logistic ModelsHealth Services AccessibilityInfant Newborn Diseases[ SDV.CAN ] Life Sciences [q-bio]/CancerCohort Studies0302 clinical medicineMESH: PregnancyMESH : Health Services AccessibilityMESH: Risk FactorsAdrenal Cortex HormonesPregnancyRisk FactorsMESH: Maternal Health ServicesMESH : Socioeconomic FactorsMedicineChildbirthRupture of membranesMESH : FemaleMESH: Cohort StudiesMESH : Infant Newborn Diseaseseducation.field_of_studyMESH: Health Services Accessibility030219 obstetrics & reproductive medicineMESH: Middle AgedObstetricsMESH: Infant NewbornSmokingAge FactorsMiddle AgedMESH : AdultMESH : Risk Factors3. Good healthMESH : SmokingMESH : Infant PrematureMESH: Young AdultGestationFemaleFranceInfant PrematureMESH: Infant PrematureAdultmedicine.medical_specialtyMESH: SmokingMESH: Socioeconomic FactorsReferralAdolescentPopulationMESH : Young AdultMESH : Cohort StudiesMESH: Infant Newborn Diseases[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Infant NewbornMESH: Adrenal Cortex HormonesMESH : Adrenal Cortex Hormones03 medical and health sciencesYoung Adult030225 pediatricsMESH : AdolescentVery Preterm BirthHumansMaternal Health ServicesMESH : Middle AgededucationMESH : FranceMESH: AdolescentMESH: Age FactorsPregnancyMESH: Humansbusiness.industryMESH : HumansInfant NewbornMESH: Adultmedicine.diseaseMESH: FranceMESH : PregnancyLogistic ModelsSocioeconomic FactorsPediatrics Perinatology and Child HealthMESH : Age FactorsbusinessMESH: FemaleMESH : Maternal Health ServicesMESH : Logistic Models
researchProduct

The EORTC computer-adaptive tests measuring physical functioning and fatigue exhibited high levels of measurement precision and efficiency

2013

Objectives: The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group is developing a computer-adaptive test (CAT) version of the EORTC Quality of Life Questionnaire (QLQ-C30). We evaluated the measurement properties of the CAT versions of physical functioning (PF) and fatigue (FA) and compared these with the corresponding QLQ-C30 scales. Study Design and Setting: Based on international samples of more than 1,000 cancer patients, we simulated CAT administration of varying numbers of items and compared the resulting scores with those based on all items in the respective item pools. Furthermore, the relative validity (RV) of CATs was compared with that of th…

MESH: FatigueMaleEpidemiologyMESH: Aged 80 and over0302 clinical medicinePhysical functioningQuality of lifeNeoplasmsSurveys and QuestionnairesActivities of Daily LivingStatisticsMESH: NeoplasmsDiagnosis Computer-Assisted030212 general & internal medicineFatigueReliability (statistics)MathematicsMESH: AgedAged 80 and overMESH: Middle AgedMiddle Agedhumanities3. Good healthMESH: Reproducibility of ResultsLevel of measurementMESH: Young AdultData Interpretation Statistical030220 oncology & carcinogenesis/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemaleAdultmedicine.medical_specialtyAdolescentMean squared errorSensitivity and SpecificityYoung Adult03 medical and health sciencesSDG 3 - Good Health and Well-beingotorhinolaryngologic diseasesmedicineHumansMESH: Surveys and QuestionnairesAgedMESH: AdolescentMESH: HumansMESH: Activities of Daily LivingMESH: Diagnosis Computer-AssistedMESH: Quality of LifeReproducibility of ResultsMESH: Adultsocial sciencesMESH: MaleMESH: Sensitivity and SpecificitySample size determinationQuality of LifePhysical therapy[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieComputerized adaptive testingMESH: Data Interpretation StatisticalMESH: FemaleRelative validity
researchProduct

Associations between cognitive performance and the rehabilitation, medical care and social support provided to French children with Prader-Willi synd…

2020

International audience; Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder with a characteristic behavioural phenotype. A multidisciplinary approach to care is required to prevent multiple medical complications in individuals affected by PWS. The aim of this study was to describe the rehabilitation, medical care, educational and social support provided to school-aged French PWS patients with varying neuropsychological profiles. Data were obtained from a French multicentre study that included patients aged 4-20 years with diverse genetic syndromes. Nineteen PWS subjects with a mean age of 9.2 years were included. The mean full-scale intellectual quotient (IQ) was 58 (W…

Male0301 basic medicinemedicine.medical_treatmentIntellectual disabilityMESH: CognitionCBCL030105 genetics & heredityCognitionMultidisciplinary approachMESH: ChildIntellectual disabilityMedicineChildGenetics (clinical)RehabilitationMESH: Hormone Replacement TherapyNeurological RehabilitationNeuropsychologyWechsler Adult Intelligence ScaleGeneral Medicine3. Good healthMESH: Young AdultChild PreschoolEducation SpecialFemaleFrancePrader-Willi SyndromeOccupational therapymedicine.medical_specialtyAdolescentHormone Replacement TherapyMESH: Social Support[SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human geneticsYoung Adult03 medical and health sciencesSocial supportMESH: Neurological RehabilitationGeneticsHumansPsychiatryMESH: AdolescentMESH: Humansbusiness.industryMESH: Child PreschoolSocial Supportmedicine.diseaseMESH: MaleMESH: FrancePatient care management030104 developmental biologyMESH: Education Special[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticsMESH: Prader-Willi SyndromebusinessMESH: FemaleEuropean Journal of Medical Genetics
researchProduct

Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension:A Double-Blind Placebo-controlled Clinical Trial

2020

Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical outcomes was unknown.\ud \ud Objectives: To evaluate the effect of oral treprostinil compared with placebo on time to first adjudicated clinical worsening event in participants with PAH who recently began approved oral monotherapy.\ud \ud Methods: In this event-driven, double-blind study, we randomly allocated 690 participants (1:1 ratio) with PAH to receive placebo or oral treprostinil extended-release tablets three times daily. Eligible participants were using approved oral monotherapy for over 30 days before randomization and had a 6-minute-walk dista…

MaleAdministration OralOral treprostinilCritical Care and Intensive Care MedicinePulmonary arterial hypertension[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractcombination therapyoralepoprostenol0302 clinical medicinepulmonary arterial hypertensionmiddle agedClinical endpointdouble-blind methodMESH: Double-Blind MethodFamilial Primary Pulmonary Hypertension030212 general & internal medicinehumansMESH: AgedMESH: Middle AgedEpoprostenol/analogs & derivativesadultHazard ratioMiddle Aged[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencesantihypertensive agents3. Good healthagedfemaleMESH: Young Adultoral treprostinilMESH: Administration Oralyoung adultFemalePulmonary Arterial Hypertension/drug therapymedicine.drugAdultPulmonary and Respiratory MedicineMESH: Pulmonary Arterial Hypertensionmedicine.medical_specialtyRandomizationAdolescentclinical study; combination therapy; oral treprostinil; pulmonary arterial hypertension; sequential therapy; administration oral; adolescent; adult; aged; antihypertensive agents; double-blind method; epoprostenol; female; humans; male; middle aged; placebos; pulmonary arterial hypertension; young adultSequential therapyMESH: PlacebosMESH: EpoprostenolLower riskPlaceboadministrationClinical studyYoung Adult03 medical and health sciencesDouble-Blind Method[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmaleInternal medicineplacebosmedicineHumansCombination therapyAdverse effectPlacebos/therapeutic useAgedMESH: AdolescentPulmonary Vascular DiseaseMESH: Antihypertensive AgentsMESH: Humanssequential therapybusiness.industryMESH: AdultOriginal Articlesclinical studyMESH: MaleClinical trial030228 respiratory systemadolescentAntihypertensive Agents/administration & dosagebusinessMESH: FemaleTreprostinil
researchProduct

Survival of European children and young adults with cancer diagnosed 1995-2002

2009

This study analyses survival in 40,392 children (age 0-14 years) and 30,187 adolescents/young adults (age 15-24 years) diagnosed with cancer between 1995 and 2002. The cases were from 83 European population-based cancer registries in 23 countries participating in EUROCARE-4. Five-year survival in countries and in regional groupings of countries was compared for all cancers combined and for major cancers. Survival for 15 rare cancers in children was also analysed. Five-year survival for all cancers combined was 81% in children and 87% in adolescents/young adults. Between-country survival differences narrowed for both children and adolescents/young adults. Relative risk of death reduced signi…

MaleCancer ResearchPediatricsMESH : Child PreschoolAdolescentsMESH: Epidemiologic Methods[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineMESH : ChildNeoplasmsMESH: ChildEpidemiologyMESH: NeoplasmsMESH : Female030212 general & internal medicineYoung adultChildChildrenChildren & young adults; Cancer survivalMESH : InfantPopulation-based cancer registriesChildren & young adultsMESH: Infant3. Good healthEuropeEastern europeanOncologyMESH: Young AdultChild Preschool030220 oncology & carcinogenesisMESH : Rare DiseasesRare tumoursFemaleMESH: Rare Diseasesmedicine.medical_specialtyAdolescentMESH : MaleMESH : EuropeMESH : Young AdultSocio-culturale[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Epidemiologic MethodsYoung Adult03 medical and health sciencesRare DiseasesSDG 3 - Good Health and Well-beingMESH : AdolescentmedicineHumansPreschoolAdolescents; Cancer survival; Children; Europe; Population-based cancer registries; Rare tumours; Young adults; Adolescent; Child; Child Preschool; Epidemiologic Methods; Europe; Female; Humans; Infant; Male; Neoplasms; Rare Diseases; Young Adult; Oncology; Cancer ResearchSurvival analysisMESH: AdolescentMESH: Humansbusiness.industryMESH: Child PreschoolMESH : HumansInfantCancermedicine.diseaseMESH : NeoplasmsCancer survivalMESH: MaleCancer registryEl NiñoRelative riskMESH: EuropeEpidemiologic MethodsbusinessMESH: FemaleYoung adults
researchProduct

The genomic and clinical landscape of fetal akinesia

2020

International audience; Fetal akinesia has multiple clinical subtypes with over 160 gene associations, but the genetic etiology is not yet completely understood.Methods: In this study, 51 patients from 47 unrelated families were analyzed using next-generation sequencing (NGS) techniques aiming to decipher the genomic landscape of fetal akinesia (FA).Results: We have identified likely pathogenic gene variants in 37 cases and report 41 novel variants. Additionally, we report putative pathogenic variants in eight cases including nine novel variants. Our work identified 14 novel disease-gene associations for fetal akinesia: ADSSL1, ASAH1, ASPM, ATP2B3, EARS2, FBLN1, PRG4, PRICKLE1, ROR2, SETBP1…

MaleCandidate geneMyopathyVARIANTSFetal akinesiaMESH: Ryanodine Receptor Calcium Release Channel0302 clinical medicineMESH: ChildGuanine Nucleotide Exchange FactorsMESH: Guanine Nucleotide Exchange FactorsExomeCopy-number variationChildExomeMESH: High-Throughput Nucleotide SequencingGenetics (clinical)GeneticsArthrogryposisArthrogryposis0303 health sciencesMESH: Infant NewbornMESH: Genetic Predisposition to DiseaseHigh-Throughput Nucleotide SequencingRNA-Binding ProteinsMESH: Infant3. Good healthFetal DiseasesCopy-number variationMESH: Fetal DiseasesMESH: Young AdultChild PreschoolASAH1FemaleMESH: DNA Copy Number Variationsmedicine.symptomAdultGENETICSAdolescentDNA Copy Number VariationsMESH: Trans-ActivatorsMESH: ArthrogryposisBiologyASPMYoung Adult03 medical and health sciencesMuscular DiseasesmedicineHumansGenetic Predisposition to DiseaseGene030304 developmental biologyMESH: Adolescent[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/PediatricsMESH: HumansMUTATIONSMESH: Child PreschoolInfant NewbornMESH: Muscular DiseasesInfantNEMALINE MYOPATHYRyanodine Receptor Calcium Release ChannelMESH: Adultmedicine.diseaseCongenital myopathyMESH: MaleMESH: RNA-Binding Proteins[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticsDISTAL ARTHROGRYPOSISTrans-ActivatorsMESH: Female030217 neurology & neurosurgery
researchProduct

Medical pre-hospital management reduces mortality in severe blunt trauma: a prospective epidemiological study

2011

International audience; INTRODUCTION: Severe blunt trauma is a leading cause of premature death and handicap. However, the benefit for the patient of pre-hospital management by emergency physicians remains controversial because it may delay admission to hospital. This study aimed to compare the impact of medical pre-hospital management performed by SMUR (Service Mobile d'Urgences et de Réanimation) with non-medical pre-hospital management provided by fire brigades (non-SMUR) on 30-day mortality. METHODS: The FIRST (French Intensive care Recorded in Severe Trauma) study is a multicenter cohort study on consecutive patients with severe blunt trauma requiring admission to university hospital i…

MaleEmergency Medical ServicesTime FactorsMESH : AgedMESH : Prospective StudiesPoison controlCritical Care and Intensive Care Medicine0302 clinical medicineInjury Severity ScorePatient AdmissionEmergency medical services[ SHS.INFO ] Humanities and Social Sciences/Library and information sciences030212 general & internal medicineHospital MortalityProspective StudiesProspective cohort studyMESH: Treatment OutcomeMESH: AgedMESH: Middle AgedMortality rate[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieMESH : Patient AdmissionMESH : AdultMiddle Aged3. Good healthMESH : Wounds and InjuriesIntensive Care UnitsTreatment OutcomeBlunt traumaMESH: Young AdultBlunt traumaMESH: Emergency Medical ServicesInjury Severity ScoreMESH : Injury Severity ScoreFranceMESH: FirefightersMESH : Intensive Care UnitsCohort studyMESH : Time FactorsAdultmedicine.medical_specialtyAdolescentMESH : Male[SHS.INFO]Humanities and Social Sciences/Library and information sciencesMESH: Injury Severity ScoreMESH : Young AdultMESH : Treatment Outcome[SHS.INFO] Humanities and Social Sciences/Library and information sciencesMESH : Hospital Mortality03 medical and health sciencesYoung AdultIntensive careMESH : AdolescentmedicineHumansMESH : Emergency Medical ServicesMESH : Middle AgedMESH: Hospital MortalityIntensive care medicineMESH : FranceAgedMESH: AdolescentMESH: Humansbusiness.industryMESH: Patient AdmissionResearchMESH : HumansMESH: Time Factors030208 emergency & critical care medicineMESH: AdultMESH: MaleMESH: Prospective StudiesMESH: France[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieMESH: Wounds and InjuriesFirefightersEmergency medicineWounds and InjuriesMESH: Intensive Care Units[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieMESH : FirefightersbusinessCritical Care
researchProduct